Parallel distribution in pharmaceuticals creates competition in a business where patents provide the rights owner with a monopoly. This is good for the European economy, good for health care systems and good for patients. The European Association of Euro-Pharmaceutical Companies (EAEPC) is the only Brussels-based non-profit organisation which brings together the licensed European pharmaceutical parallel distribution industry, championing the industry's achievements and the benefits of its products.

Parallel distributors are registered as pharmaceutical wholesalers who supply the intra-European market (often called 'exporters') or who place medicines from another country market in their market of destination (often called 'importers') who must in addition hold a manufacturing authorisation for the necessary repackaging.

Through the direct membership of 14 national associations and 21 individual companies, the EAEPC encompasses about 100 firms from 23 countries engaged in parallel distribution in the European Economic Area (EEA), representing 80 percent of the volume of the overall industry. EAEPC member companies are nearly all privately owned small- to medium-sized enterprises (SMEs).

All products handled by EAEPC members have national and/or EU regulatory approval and are exclusively sourced from and sold to European Economic Area (EEA) countries using only authorised trade channels.